Stockscreener 앱 받기
25.88
3.11%
-0.83
시간 외 거래:
26.45
0.57
+2.20%
Greenwich Lifesciences Inc 주식(GLSI)의 최신 뉴스
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences expands Phase III trial to City of Hope sites - Investing.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
City of Hope joins breast cancer trial, widening access across US sites - Stock Titan
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com Canada
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - GlobeNewswire Inc.
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com UK
Breast cancer trial sees under 1% yearly recurrences in GLSI-100 arm - Stock Titan
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com South Africa
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - Sahm
Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
GLSI Should I Buy - Intellectia AI
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Greenwich LifeSciences reports 33% rise in trial screening rate By Investing.com - Investing.com Canada
Greenwich LifeSciences reports 33% rise in trial screening rate - Investing.com South Africa
Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial - Traders Union
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - GlobeNewswire
US Stocks Recap: Is Greenwich LifeSciences Inc undervalued by DCF analysisTrade Exit Summary & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Sentiment: Can Greenwich LifeSciences Inc expand into new marketsOptions Play & Long-Term Safe Investment Ideas - baoquankhu1.vn
GLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (GLSI) - Stock Traders Daily
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting By Investing.com - Investing.com Australia
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting - Investing.com Nigeria
Rally Mode: Is BTCM a cyclical or defensive stockWall Street Watch & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Greenwich lands 2 AACR 2026 slots, first with FLAMINGO-01 Steering Committee - Stock Titan
GLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 - ChartMill
Analysis Recap: Is SPRY stock showing strong momentumQuarterly Market Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January - MarketBeat
How interest rate cuts could boost Greenwich LifeSciences Inc. stockJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
GLSI PE Ratio & Valuation, Is GLSI Overvalued - Intellectia AI
Avoiding Lag: Real-Time Signals in (GLSI) Movement - Stock Traders Daily
How buybacks impact Greenwich LifeSciences Inc. stock valueWall Street Watch & AI Powered Market Entry Ideas - mfd.ru
Aug Update: Will Greenwich LifeSciences Inc stock benefit from M A2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Is Greenwich LifeSciences Inc. stock trending bullishRate Hike & Smart Money Movement Tracker - mfd.ru
Analyst Upgrade: Is Lavoro Limiteds growth already priced inJuly 2025 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for GLSI Earnings - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):